Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
New Mexico Cancer Care Alliance
1327
mi
from 43215
Albuquerque, NM
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
New Mexico Cancer Care Alliance
1327
mi
from 43215
Albuquerque, NM
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Medical Center
549
mi
from 43215
Stony Brook, NY
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Medical Center
549
mi
from 43215
Stony Brook, NY
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
SCRI-Oncology Hematology Care
87
mi
from 43215
Cincinnati, OH
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
SCRI-Oncology Hematology Care
87
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
138
mi
from 43215
Cleveland, OH
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
138
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma
848
mi
from 43215
Oklahoma City, OK
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma
848
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
416
mi
from 43215
Philadelphia, PA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
UPMC - Hillman Cancer Center
166
mi
from 43215
Pittsburgh, PA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
UPMC - Hillman Cancer Center
166
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Upstate Oncology Associates
355
mi
from 43215
Greenville, SC
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Upstate Oncology Associates
355
mi
from 43215
Greenville, SC
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute (SCRI)
333
mi
from 43215
Nashville, TN
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute (SCRI)
333
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Texas Onocolgy-Baylor Sammons Cancer Center
909
mi
from 43215
Dallas, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Texas Onocolgy-Baylor Sammons Cancer Center
909
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
UTMB Galveston
992
mi
from 43215
Galveston, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
UTMB Galveston
992
mi
from 43215
Galveston, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Houston Methodist
991
mi
from 43215
Houston, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Houston Methodist
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Cancer Care Centers of South Texas
1138
mi
from 43215
San Antonio, TX
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Cancer Care Centers of South Texas
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Hospital
1511
mi
from 43215
Salt Lake City, UT
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Hospital
1511
mi
from 43215
Salt Lake City, UT
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
296
mi
from 43215
Leesburg, VA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
296
mi
from 43215
Leesburg, VA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Providence Regional Cancer Partnership
2001
mi
from 43215
Everett, WA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Providence Regional Cancer Partnership
2001
mi
from 43215
Everett, WA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Fred Hutchinson Cancer Research Center
2007
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Green Bay Oncology
403
mi
from 43215
Green Bay, WI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Green Bay Oncology
403
mi
from 43215
Green Bay, WI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Froedtert Hospital, Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Froedtert Hospital, Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
330
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
City of Hope
1955
mi
from 43215
Duarte, CA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
City of Hope
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Center
2101
mi
from 43215
Stanford, CA
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Center
2101
mi
from 43215
Stanford, CA
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Northwestern University
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
165
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
St George Hospital
9463
mi
from 43215
Kogarah,
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
St George Hospital
9463
mi
from 43215
Kogarah,
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
SCRI - Florida Cancer Specialists North Region
842
mi
from 43215
Saint Petersburg, FL
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
SCRI - Florida Cancer Specialists North Region
842
mi
from 43215
Saint Petersburg, FL
Click here to add this to my saved trials
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine Division of Oncology
394
mi
from 43215
Saint Louis, MO
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia
A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine Division of Oncology
394
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Status: Enrolling
Updated:  12/31/1969
UAB Bone Marrow Transplantation and Cellular Therapy Program
494
mi
from 43215
Birmingham, AL
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Status: Enrolling
Updated: 12/31/1969
UAB Bone Marrow Transplantation and Cellular Therapy Program
494
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis School of Medicine
397
mi
from 43215
Saint Louis, MO
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Bone Marrow Aspirate Concentration in Posterior Cervical Fusion
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
129
mi
from 43215
Cleveland, OH
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
126
mi
from 43215
Cleveland, OH
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
126
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
1644
mi
from 43215
Scottsdale, AZ
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
1644
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Colorado Blood Cancer Institute
1161
mi
from 43215
Denver, CO
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Colorado Blood Cancer Institute
1161
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Winship Cancer Institute of Emory School of Medicine
432
mi
from 43215
Atlanta, GA
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Winship Cancer Institute of Emory School of Medicine
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
John Theruer Cancer Center at Hackensack University Medical Center
475
mi
from 43215
Hackensack, NJ
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
John Theruer Cancer Center at Hackensack University Medical Center
475
mi
from 43215
Hackensack, NJ
Click here to add this to my saved trials
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
480
mi
from 43215
New York, NY
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania:Abramson Cancer Center
414
mi
from 43215
Philadelphia, PA
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania:Abramson Cancer Center
414
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
348
mi
from 43215
Nashville, TN
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
348
mi
from 43215
Nashville, TN
Click here to add this to my saved trials
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy
Status: Enrolling
Updated:  12/31/1969
Case Comprehensive Cancer Center
129
mi
from 43215
Cleveland, OH
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy
Status: Enrolling
Updated: 12/31/1969
Case Comprehensive Cancer Center
129
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1955
mi
from 43215
Duarte, CA
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1955
mi
from 43215
Duarte, CA
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2107
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1154
mi
from 43215
Aurora, CO
Click here to add this to my saved trials